Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1161-1180 of 2,251 trials

Posaconazole for Fungal Infection Prevention in Stem Cell Transplant Patients

We are studying whether posaconazole can effectively prevent fungal infections in patients receiving stem cell transplants. This research aims to understand how well the medication works and its impact on patient recovery.

Healthy Participants>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Diabetic Ketoacidosis: Comparing Ringer Lactate and Saline

We are studying whether Ringer Lactate is more effective than isotonic saline in treating severe diabetic ketoacidosis in ICU patients. This may help improve treatment outcomes for those affected.

Diabetic Ketoacidosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Fanconi Anaemia: Gene Therapy Study

We are evaluating the long-term safety and effects of a gene therapy using modified cells in patients with Fanconi Anaemia Subtype A. This study aims to understand how well the treatment works and its impact on blood health over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

HIV Research: Topiramate Treatment

We are investigating whether topiramate can help activate hidden HIV in people on antiretroviral therapy. The study also examines the safety of this medication and how various factors may influence its effects.

HIV-1 Infection≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Advanced Solid Tumors: ART0380 Oral Treatment

We are studying the safety and effectiveness of the oral medication ART0380 for patients with advanced or metastatic solid tumors. This includes testing it alone and in combination with other drugs to see how well it works.

Advanced or Metastatic Solid TumoursSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

Rheumatoid Arthritis6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Advanced Cancer: IO102-IO103 with Pembrolizumab

We are studying a new treatment combination for patients with metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, or metastatic urothelial bladder cancer. The goal is to evaluate its effectiveness and safety as a first-line therapy.

Metastatic Squamous Cell Carcinoma of Head and NeckMetastatic Urothelial Bladder CancerMetastatic Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesOncology

Myelofibrosis: Tasquinimod Treatment Study

We are studying tasquinimod in patients with myelofibrosis who are not responding to current treatments. The goal is to see if it can safely reduce spleen size and improve symptoms.

Myelofibrosis3-6 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Multiple Myeloma: Selinexor with Dexamethasone and Bortezomib

We are studying different combinations of Selinexor, Dexamethasone, and Bortezomib for patients with hard-to-treat multiple myeloma. Our goal is to see how well these treatments work and how safe they are.

Multiple MyelomaRelapsed/Refractory Multiple MyelomaPenta-Refractory Multiple Myeloma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Locally-Advanced Rectal Cancer: Tailored Treatment Study

We are studying a personalized treatment plan for patients with locally-advanced rectal cancer who respond well to initial chemotherapy. The goal is to see if this approach maintains effective surgery outcomes while reducing treatment intensity.

Rectal Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Alzheimer's Disease: Understanding Tau Spread and Language Function

We are studying how tau protein spreads in the brain during different stages of Alzheimer's disease and its impact on language abilities. This research may help us understand cognitive changes in patients.

Early Alzheimer's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesNeurologyPsychiatry

Sodium Thiosulfate Injections for Ectopic Calcifications

We are studying whether injections of sodium thiosulfate can help reduce calcifications and ossifications in patients with certain autoimmune conditions. This trial will also look at the treatment's safety and its impact on pain and quality of life.

Ectopic Calcification and Ossification>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Esophageal Adenocarcinoma: Metformin Treatment

We are studying whether metformin can enhance the immune response in patients with esophageal adenocarcinoma receiving chemoradiotherapy. This research may help improve treatment effectiveness and patient outcomes.

Oesophageal Adenocarcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Daratumumab for Very High-Risk T-Cell Acute Lymphoblastic Leukemia

We are studying whether adding daratumumab to standard treatment helps adults with very high-risk T-ALL achieve better disease control. This trial will also assess the safety and effectiveness of this combination therapy.

Very High-Risk T-Lineage Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Hodgkin's Lymphoma: Atezolizumab and BEGEV Treatment

We are studying a new combination treatment for patients with relapsed or refractory Hodgkin's lymphoma to see if it helps improve response rates before stem-cell transplantation. This trial will also evaluate the safety and tolerability of this treatment approach.

Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Mantle Cell Lymphoma: Loncastuximab Tesirine Treatment

We are studying whether loncastuximab tesirine can improve outcomes for patients with relapsed or refractory mantle cell lymphoma after immunochemotherapy. The trial also looks at the safety of this treatment and its effectiveness in reducing disease presence.

Mantle Cell LymphomaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Plasmablastic Lymphoma: Daratumumab with Bortezomib and Dexamethasone

We are studying a combination of daratumumab, bortezomib, and dexamethasone for patients with relapsed or refractory plasmablastic lymphoma. The goal is to see if this treatment improves outcomes for those who cannot undergo stem cell transplantation.

Relapsed or Refractory Plasmablastic Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

Castration-resistant Prostate Cancer6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Myelodysplastic Syndrome: Targeted Treatment After Stem Cell Transplant

We are studying a new approach to prevent relapse and improve survival in patients with myelodysplastic syndrome after stem cell transplantation. The trial focuses on those with minimal residual disease to see if personalized treatment can help.

Myelodysplastic Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Solid Tumors: 68Ga-FAPI-46 PET-CT Imaging Study

We are testing a new imaging method to see if it can better identify issues in solid tumors when previous scans were unclear. This study aims to improve risk assessment and safety for patients with various tumor types.

Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology